First Manhattan Co. increased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 35.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 376,395 shares of the specialty pharmaceutical company’s stock after buying an additional 98,300 shares during the period. First Manhattan Co. owned 3.23% of ANI Pharmaceuticals worth $17,615,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in ANI Pharmaceuticals by 90.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 91,514 shares of the specialty pharmaceutical company’s stock worth $5,548,000 after buying an additional 43,534 shares during the period. AQR Capital Management LLC acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth $252,000. Thrivent Financial for Lutherans increased its stake in ANI Pharmaceuticals by 5.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,300 shares of the specialty pharmaceutical company’s stock worth $261,000 after buying an additional 240 shares during the period. Perkins Capital Management Inc. acquired a new stake in ANI Pharmaceuticals during the first quarter worth $1,097,000. Finally, CAPROCK Group Inc. increased its stake in ANI Pharmaceuticals by 6.7% in the first quarter. CAPROCK Group Inc. now owns 4,591 shares of the specialty pharmaceutical company’s stock worth $227,000 after buying an additional 287 shares during the period. Institutional investors own 56.03% of the company’s stock.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) traded down 0.11% during trading on Friday, reaching $44.01. The company had a trading volume of 69,106 shares. The stock has a market cap of $512.19 million, a PE ratio of 96.30 and a beta of 3.08. ANI Pharmaceuticals, Inc. has a 52-week low of $42.23 and a 52-week high of $70.92. The company has a 50-day moving average price of $46.91 and a 200 day moving average price of $50.31.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.19. The company had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. ANI Pharmaceuticals’s quarterly revenue was up 43.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.11 EPS. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “ANI Pharmaceuticals, Inc. (ANIP) Shares Bought by First Manhattan Co.” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://stocknewstimes.com/2017/08/12/first-manhattan-co-buys-98300-shares-of-ani-pharmaceuticals-inc-anip-updated.html.
A number of research firms recently weighed in on ANIP. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 3rd. Canaccord Genuity began coverage on ANI Pharmaceuticals in a research report on Monday, July 31st. They set a “buy” rating and a $60.00 target price on the stock. Roth Capital set a $56.00 target price on ANI Pharmaceuticals and gave the stock a “hold” rating in a research report on Saturday, May 6th. Guggenheim reiterated a “buy” rating and set a $80.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. Finally, ValuEngine cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. ANI Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $65.33.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.